Fortrea Q3: $0.6M GAAP Profit, $558M Backlog Cut, Buying Growth With $45M Deal
FTRE has more than doubled off its 52-week low of $8.55 on elevated volume (3.0× avg).
Summary
Fortrea posted Q3 revenue of $691.5M and a $0.6M GAAP profit, with $72.7M of nine-month operating cash flow, while cutting backlog by about $558M and closing a $45M early-phase acquisition.
Key Events · Earnings and Guidance · FTRE
-
Q3 Swings to Small GAAP Profit
Revenue came in at $691.5M versus $701.3M a year ago, but net income of $0.6M compared with a $15.9M loss; the nine-month net loss narrowed to $36.2M from $953.7M.
-
Operating Cash Flow Turns Positive
The first nine months of 2026 produced $72.7M of operating cash versus $15.6M used in the prior-year period, lifting cash and equivalents to $220.6M from $174.6M at December 31, 2025.
-
Backlog Cut by $558M
Backlog stood at $7.3B as of September 30, 2026 after a roughly $558M reduction for estimated scope and study-delivery changes; management says it was not driven by any recent material customer communication.
-
Legal Overhangs Cleared
The securities class action was dismissed in full with prejudice on September 28, 2026, and the Clario/Thermo Fisher suit over the CFO appointment settled in August 2026 with no material impact.
Analysis · FTRE · Industrial Applications And Services
The real story here is cash: Fortrea swung to a small GAAP profit of $0.6M versus a $15.9M loss a year ago on revenue of $691.5M, and the first nine months of 2026 generated $72.7M of operating cash versus $15.6M used last year. Against that, the company cut backlog by roughly $558M to $7.3B for scope and study-delivery changes, which management says was not driven by any recent material customer communication but does trim the forward revenue base. Two legal overhangs also cleared: the securities class action was dismissed with prejudice on September 28, 2026, and the Clario/Thermo Fisher suit over the CFO's appointment settled in August with no material impact. Meanwhile, the $45M cash purchase of Worldwide Clinical Trials' Early Phase Services division, closed October 19, 2026, adds clinical pharmacology and bioanalytical lab capacity funded from the $220.6M cash balance.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FTRE was trading at $23.14 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $8.55 to $26.16. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.